STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Genetic testing	$ 2,168,744	$ 2,154,785
Other	260,868	81,602
Total revenue	2,429,612	2,236,387
Cost of revenue	1,632,497	1,328,538
Gross profit	797,115	907,849
Operating expenses:
Research and development	721,568	1,311,877
Selling, general and administrative	6,564,807	4,150,607
Amortization of intangibles	109,266	115,453
Total operating expenses	7,395,641	5,577,937
Loss from operations	(6,598,526)	(4,670,088)
Other income (expense):
Interest income	6,804	4,485
Interest expense	(472,186)	(454,481)
Gain on disposal of asset	5,975	0
Total other income (expense)	(459,407)	(449,996)
Loss before income taxes	(7,057,933)	(5,120,084)
Benefit for income taxes	0	0
Net loss	$ (7,057,933)	$ (5,120,084)
Basic and diluted net loss per common share	$ (0.08)	$ (0.14)
Weighted average common shares outstanding, basic and diluted	90,449,758	36,754,679